Worldwide Clinical Trials (Worldwide), a privately held, leading global, full-service contract research organization, has announced the closing of its previously announced recapitalization that gives funds managed by Kohlberg & Company, LLC, a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, a majority stake in the company. Middle-market private equity firm TJC, which has been Worldwide’s sole investor since 2007, retains a meaningful minority equity stake in the CRO.

Latham & Watkins LLP represented NB Capital Solutions in the transaction with a New York capital markets team led by partners Stelios Saffos, Pete Sluka, and Andrew Blumenthal, with associates Ian Lachow and Emma Gilmore. Advice was also provided on tax matters by Century City partner Pardis Zomorodi.